Compare Abeona Therapeutics Inc (ABEO) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Sprott Uranium Miners ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Sprott Uranium Miners ETF trades at $50.81. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | URNM | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $83.99 |
52-Week Low | $4.17 | $44.14 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
URNM trades at $53.56, up 1.38% today, but technical indicators signal a bearish trend with moving averages showing strong sell signals. The ETF is positioned at the intersection of AI-driven electricity demand and nuclear energy growth, with recent news highlighting uranium's role in powering data centers. Key support lies at $52, while resistance is near $54.
Outlook is mixed: long-term growth is supported by nuclear energy demand, but short-term risks include volatility in uranium prices and miner equity valuations. Investment opportunity hinges on the AI power narrative, yet caution is warranted due to technical weakness and concentrated miner exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
